^
BIOMARKER:
BRAF V600E
i
Other names: BRAF, B-raf proto-oncogene, B-raf proto-oncogene, Serine/threonine kinase, V-Raf murine sarcoma viral oncogene homolog B, Serine/threonine-protein kinase B-Raf, Proto-oncogene B-Raf, BRAF1, RAFB1, B-raf proto-oncogene Serine/threonine-protein kinase, Murine sarcoma viral (V-Raf) oncogene homolog B1, B-raf serine/threonine-protein, 94 KDa B-raf protein, B-RAF1
Entrez ID:
Related biomarkers:
BRAF V600E
Melanoma
Immunotherapy
Resistant
:
C3
SID 2021 - 3wk
BRAF V600E
CRC
cetuximab + binimetinib + encorafenib
Sensitive
:
A1
BRAF V600E
CRC
cetuximab + encorafenib
Sensitive
:
A1
BRAF V600E
Melanoma
dabrafenib
Sensitive
:
A1
BRAF V600E
NSCLC
trametinib + dabrafenib
Sensitive
:
A1
BRAF V600E
Thyroid Gland Anaplastic Carcinoma
trametinib + dabrafenib
Sensitive
:
A1
BRAF V600E
Thyroid Gland Anaplastic Carcinoma
dabrafenib
Sensitive
:
A1
BRAF V600E
Melanoma
trametinib + dabrafenib
Sensitive
:
A1
BRAF V600E
Melanoma
vemurafenib + cobimetinib
Sensitive
:
A1
BRAF V600E
Melanoma
vemurafenib
Sensitive
:
A1
BRAF V600E
Melanoma
trametinib
Sensitive
:
A1
BRAF V600E
Melanoma
binimetinib + encorafenib
Sensitive
:
A1
BRAF V600E
NSCLC
vemurafenib
Sensitive
:
A2
BRAF V600E
Ganglioglioma
trametinib + dabrafenib
Sensitive
:
A2
BRAF V600E
Ganglioglioma
vemurafenib + cobimetinib
Sensitive
:
A2
BRAF V600E
Ganglioglioma
vemurafenib
Sensitive
:
A2
BRAF V600E
Cutaneous Melanoma
trametinib + dabrafenib
Sensitive
:
A2
BRAF V600E
Biliary Tract Cancer
trametinib + dabrafenib
Sensitive
:
A2
BRAF V600E
Astrocytoma
trametinib + dabrafenib
Sensitive
:
A2
BRAF V600E
Astrocytoma
vemurafenib + cobimetinib
Sensitive
:
A2
BRAF V600E
Astrocytoma
cobimetinib
Sensitive
:
A2
BRAF V600E
Astrocytoma
vemurafenib
Sensitive
:
A2
BRAF V600E
Astrocytoma
trametinib
Sensitive
:
A2
BRAF V600E
Astrocytoma
dabrafenib
Sensitive
:
A2
BRAF V600E
Ganglioglioma
cobimetinib
Sensitive
:
A2
VERI is free for non-commercial use, no login needed.
Content on this site is for research purposes only and is not intended  to be a substitute for medical advice.
For commercial access, including additional premium features, please contact us.
By using VERI, you are agreeing to our